

1 **TITLE:** Observational study of effects of HIV Acquisition and Antiretroviral Treatment on Biomarkers
2 of Systemic Immune Activation

3
4 **AUTHORS:** Ewelina Kosmider^{1*}, Jackson Wallner^{2*}, Ana Gervassi², Rachel A Bender Ignacio^{1,3,4},
5 Delia Pinto-Santini¹, German Gornalusse⁵, Urvashi Pandey^{1,5}, Florian Hladik^{1,3,5}, Paul T. Edlefsen¹,
6 Javier R. Lama^{4,6}, Ann C. Duerr¹, Lisa M. Frenkel^{1,2,3,4,8,9}

7 *Authors contributed equally

8
9 ¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

10 ² Seattle Children's Research Institute, Seattle, WA, USA

11 ³Department of Medicine, University of Washington, Seattle, WA, USA

12 ⁴Department of Global Health, University of Washington, Seattle, WA, USA

13 ⁵Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, USA

14 ⁶Asociación Civil Impacta Salud y Educación, Lima, Perú

15 ⁷Universidad de San Marcos, Lima, Peru

16 ⁸Department of Pediatrics, University of Washington, Seattle, WA, USA

17 ⁹Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA

18

19 **CORRESPONDING AUTHOR:** Lisa M. Frenkel

20

21 **SHORT TITLE:** Immune Biomarkers Pre- vs. Post-HIV

22

23 **KEY WORDS:** HIV, Systemic inflammation, Biomarkers, Acute HIV infection, Immediate ART or

24 Test-and-treat

25 **ABSTRACT:**

26

27 **Objective:** Assess whether biomarkers of systemic inflammation are associated with HIV acquisition or
28 with the timing of ART initiation (“immediate”, at diagnosis, versus “deferred”, at 24 weeks post-
29 diagnosis) in men-who-have-sex-with-men (MSM) and transgender women.

30

31 **Design:** A retrospective study comparing inflammatory biomarkers in participants’ specimens collected
32 before and after ≥ 2 years of effective ART.

33 **Methods:** Inflammatory biomarkers were measured in four longitudinally collected plasma specimens,
34 including two plasma specimens collected from each participant before and two after HIV acquisition and
35 confirmed ART-suppression. Biomarkers were quantified by enzyme-linked immuno-assay or Meso
36 Scale Discovery. Statistical measures compared intra-participant and between-group changes in
37 biomarkers.

38 **Results:** Across 50 participants, the levels of C-reactive protein (CRP), monocyte chemo-attractant
39 protein-1, tumor necrosis factor- α and interferon gamma-induced protein-10 significantly increased while
40 leptin and lipopolysaccharide binding protein (LBP) significantly decreased following HIV infection.
41 Randomization to deferred-ART initiation was associated with greater increases in CRP and no decreases
42 in LBP. Multiple biomarkers varied significantly within participants’ two pre-infection or two post-ART-
43 suppression specimens.

44 **Conclusions:** Acquisition of HIV appeared to induce systemic inflammation, with elevation of
45 biomarkers previously associated with infections and cardiovascular disease. Initiation of ART during the
46 early weeks of infection tempered the increase in pro-inflammatory biomarkers compared to those who
47 delayed ART for ~24 weeks after HIV diagnosis, perhaps because immediate-ART limited the size of the
48 HIV reservoir or limited immune dysregulation. Some but not all biomarkers appeared sufficiently stable

49 to assess intraparticipant changes over time. Given that pro-inflammatory biomarkers predict multiple co-
50 morbidities, our findings suggest that immediate-ART initiation may improve health outcomes.

51 **INTRODUCTION**

52
53 The progression of HIV disease to AIDS has been mitigated by antiretroviral treatment (**ART**) (1, 2, 3).
54 Despite ART, life-threatening non-AIDS-defining comorbidities associated with elevated biomarkers of
55 systemic immune activation occur at increased frequencies in people living with HIV (**PWH**) compared
56 to uninfected persons (4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14). While effective ART is associated with
57 normalization of some pro-inflammatory biomarkers, other biomarkers, particularly those associated with
58 monocyte/macrophage activation, remain elevated in PWH compared to uninfected individuals (7).
59 Studies comparing immune activation biomarkers in PWH versus uninfected persons aim to control for
60 genetic, behavioral, or other pre-existing factors (4, 7, 15). However, longitudinal studies examining these
61 factors before and following incident HIV infection are lacking. We leveraged specimens collected from
62 individuals with prospectively documented incident HIV infection (16, 17) to compare immune
63 biomarkers in specimens collected prior to HIV infection to those collected after ART suppression of
64 viral replication. Because ART prevents ongoing viral replication but does not prevent infected cells from
65 producing viral proteins and particles, we hypothesized that PWH would demonstrate greater immune
66 activation after ART suppression of viral replication compared to pre-infection values. Additionally,
67 because ART initiated during primary infection limits the size of the HIV reservoir, we hypothesized that
68 PWH initiating ART at diagnosis during acute or early primary infection (“immediate” ART) would show
69 less immune activation compared to those who “deferred” ART for ~24 weeks.

70

71 **METHODS**

72 Banked specimens from a prospective study of incident HIV infection among seronegative men-who-
73 have-sex-with-men (**MSM**) and transgender women in Lima, Peru (*Sabes* Study) (16) were utilized to
74 evaluate immune biomarkers. Participants were enrolled into the *Sabes* Study between 7/16/2013 and
75 7/31/2015 followed through 9/10/2019 (date of last 4th timepoint sample). All participants provided
76 written informed consent including consent for future use of specimens; personal identifiers were retained
77 at the study site in Lima (JRL) for participant tracking and were not available to other co-authors.

78 Participants were screened monthly for HIV acquisition by HIV antibody and nucleic acid amplification
79 testing. The estimated date of detectable infection (**EDDI**) was calculated as previously described (17,
80 18). Following HIV diagnosis, participants were randomized to initiate ART immediately (**immediate-**
81 **ART**) or to defer ART for 24 weeks (**deferred-ART**) (16).

82

83 Participants with documented incident HIV infection were selected for this sub-study in February 2020
84 (with participants data accessed on multiple dates during the preceding months) based on availability of
85 two pre- and two post-infection plasma specimens, with the rationale to evaluate immune biomarkers in
86 steady-state and avoid transient changes associated with HIV acquisition or ART initiation. Specimens
87 included one plasma sample shortly after enrollment, a second ≤ 3 months from EDDI (**Visits 1 and 2**,
88 respectively), a third ≥ 6 months and a fourth ≥ 24 months after ART suppression of plasma HIV RNA to
89 < 200 copies/mL (ART-suppression) (**Visits 3 and 4**, respectively).

90

91 Biomarkers linked to systemic inflammation and cardiovascular disease were selected for quantification:
92 C-reactive protein (**CRP**), tumor necrosis factor- α (**TNF- α**), interleukin (**IL-6**), soluble urokinase-type
93 plasminogen activator receptor (**suPAR**), interferon gamma-induced protein 10 (**IP-10**), interleukin 1 β
94 (**IL-1 β**), interleukin 8 (**IL-8**)⁷, interleukin 10 (**IL-10**) (19, 20, 21), lipopolysaccharide binding protein
95 (**LBP**) (22, 23), and markers associated with bacterial translocation (soluble cluster of differentiation 14
96 and 163 (**sCD14**, **sCD163**), and antiviral responses (interferon-gamma (**IFN- γ**), leptin, interleukin α -2a
97 (**IFN- α 2a**), monocyte chemoattractant protein-1 (**MCP-1/CCL2**)) (24). Meso Scale Discovery (**MSD**,
98 Rockville, MD) determined levels of IFN- α 2a, IFN- γ , IL-1 β , IL-6, IL-8, IL-10, IP-10, leptin, MCP-
99 1/CCL2, TNF- α , LBP, CRP, and ELISAs (R&D Systems, Minneapolis, MN) determined levels of
100 sCD14, sCD163, and suPAR in March/April 2020.

101

102 During study analysis, participants' data was accessed on multiple dates in November and December
103 2020 and throughout 2021 by multiple team members. To determine the stability of biomarkers across the

104 two pre-infection or two post-suppression time-points, a two-sided, one-sample t-test was used to
105 separately compare values within each pair of pre-infection and post-suppression specimens. Biomarker
106 levels were also compared to physiologic “normal” ranges determined by assay manufacturers or clinical
107 studies (leptin, CRP, IFN- α 2a) (25, 26). Because a prior study associated elevated plasma sCD14 levels
108 with efavirenz-based-ART(8), we further analyzed values across Visit-3 and -4 in participants switching
109 from efavirenz- to non-efavirenz-based regimens.

110
111 To identify biomarkers that differed following HIV infection despite more than six months of ART-
112 suppression, a regression analysis was conducted separately for each biomarker. Participant-specific fixed
113 effects were evaluated across timeframes defined by pre- or post-infection paired visits. To account for
114 variations within the pre- and within the post-infection specimens, variance was pooled across timeframes
115 and across people. This effectively allowed us to implement a pooled variance one-sample t-test with
116 repeated measures, treating the paired visits within the pre- or post-infection timeframe as exchangeable.
117 Unadjusted and Holm adjusted p-values and 95% confidence intervals for the change in mean marker
118 value pre- versus post-infection were calculated in R 4.2.1. Additionally, the regression model included
119 the indicator “deferred-ART” to evaluate whether the duration of infection prior to ART initiation
120 contributed to a difference in biomarkers. P-values of ≤ 0.05 were considered significant. To display
121 multiple biomarker differences on a common scale, the differences between pre- versus post-infection
122 means were divided by the pre-infection standard deviation (**SD**) for each biomarker.

123

124 **RESULTS**

125 **Participants**

126 From among a total of 216 *Sabes* participants with prospectively documented incident HIV infection 50
127 had specimens from four time-points and fulfilled ART-suppression entry criteria and were used for this
128 study of immune biomarkers. These 50 included 19 participants randomized to immediate-ART and 31
129 randomized to deferred-ART. Five participants randomized to deferred-ART initiated ART prior to 24-

130 weeks post-HIV-diagnosis due to low CD4 cell counts or other ART-qualifying events and two of these
 131 initiated ART in the immediate-ART timeframe and are included in the immediate-ART group for the
 132 “as-treated” analysis; three initiated ART between the immediate- and the deferred-ART timeframes and

Table 1: Demographic and clinical parameters of participants

	Total N=50		Range
Age at diagnosis; mean years	25.6		18-52
Gender Identity; N (%)			
Homosexual men	29 (58)		
Bisexual men	15 (30)		
Transsexual women	6 (12)		
Race/Ethnicity; N (%)			
Mixed race/Hispanic	50 (100)		
Other			
Not reported			
Time interval from EDDI* to ART in days	<u>Mean</u>		
All participants	134		16-238
Immediate group	39		16-63
Deferred group	210		182-238
	Mean	Std. deviation	95% CI
Plasma HIV RNA at HIV diagnosis (log10)	5.8	0.9	5.5, 6.0
CD4 count at HIV diagnosis (cells/uL)	464	197	152, 1203

*EDDI = estimated date of detectable HIV infection

133 were excluded from the as-treated analysis, which is reported here. The mean interval from EDDI to ART
 134 initiation for immediate-ART (N=21) and deferred-ART (N=26) groups were 39 (range:16-63) and 210
 135 days (range:182-238), respectively (**Table 1**).

136
 137
 138

139
 140 The antiretrovirals provided to study participants shifted over time: at Visit 3, 43/50 were receiving
 141 efavirenz+emtricitabine+tenofovir disoproxil and by Visit 4, 48/50 were receiving
 142 elvitegravir/cobicistat+emtricitabine+tenofovir alafenamide. Non-study ART regimens were given to nine

143 participants as medically indicated, including seven protease-inhibitor-based and two efavirenz-based
144 regimens.

145

146 **Pro-inflammatory biomarkers**

147 Prior to HIV infection the paired pre-infection biomarker levels demonstrated intraparticipant stability,
148 except for significant variability in IP-10, IL-6 and sCD163 (N=50, **Supplementary Table 1,**

149 **Supplementary Figure 1**). The mean biomarker values for most participants were within established
150 normal ranges (**Figure 1**). Outliers with elevated biomarkers observed in both pre-infection specimens

151 included IL-1 β (N=1 participant), suPAR (N=2), MCP-1/CCL2, sCD163, and CRP (N=3), TNF α (N=9)
152 and/or leptin (N=23). Following ART-suppression, intraparticipant biomarkers demonstrated stability

153 except for sCD163, leptin, IL-8, and LBP (N=50, **Supplementary Table 2, Supplementary Figure 2**).

154 The mean biomarker levels of most participants remained within established norms, except outliers with
155 both values elevated were observed for IL-1 β (N=1 participant), suPAR and sCD163 (N=4), IL-6 (N=5),
156 leptin (N=6), MCP-1/CCL2 (N=8), CRP and TNF- α (N=9) (**Figure 1**).

157

158

159 **Figure 1. Plasma biomarker levels comparing pre-HIV-infection to post-infection and antiretroviral**
160 **therapy-suppression by timing of ART initiation.** Each biomarker evaluated is shown in a separate panel,
161 with normal upper and lower ranges indicated by solid horizontal lines. The mean biomarker levels are
162 plotted for each participant's (N=50) biomarker values from two timepoints prior to HIV infection (pre-
163 acquisition) and two timepoints post-ART-suppression (>6 months and >2 years post ART suppression of
164 plasma HIV RNA to <200 c/mL). The two post-ART-suppression values also shown for "all" participants
165 and separately by the two "as-treated" groups by the time when ART was initiated, either immediately
166 upon diagnosis during primary infection (N=21) or deferred for 24 weeks after HIV diagnosis (N=26)
167 (Immediate-ART, Deferred-ART, respectively). Unadjusted p-values by a regression analysis shown (*
168 <0.01, ** < 0.05, *** < 0.001) for significant changes in mean cytokine levels between the 47
169 participants prior to HIV infection versus after ART-suppression. Holm adjusted p-values <0.001
170 indicated by (°).

171

172
173 Comparisons of all participant's (N=47) mean pre-infection biomarker values to their ART-suppressed
174 mean values by a regression analysis detected statistically significant increases in IP-10, MCP-1/CCL2,
175 TNF α , CRP and significant decreases in leptin and LBP (**Figure 1**), with differences sustained after Holm
176 adjustment for multiple comparisons in all but LBP and TNF- α (**Supplementary Table 3a**). Comparison
177 of biomarker levels by timing of ART-initiation found a difference in pre-infection to post-ART-
178 suppression by ART timing group for IFN- α 2a and CRP (**Figure 2** and **Supplementary Tables 4a**); CRP
179 increased and IFN- α 2a decreased in the deferred-ART but not in the immediate-ART group (**Figure 2**,
180 **Supplementary Table 5a, Supplementary Table 6a**). Furthermore, IP-10 and MCP-1/CCL2 increased
181 and leptin decreased in both groups, while LBP decreased in the immediate-ART group but not in the
182 deferred-ART group.

183
184 **Figure 2.** Difference between pre-HIV-infection and post-ART suppression biomarker values by timing
185 of antiretroviral therapy (ART) initiation. Biomarker levels from two specimens before HIV infection and
186 two after ART-suppression were separately compared for all participants (shown in black (N=47)), and
187 participants separated into two groups: those who started ART immediately upon HIV-diagnosis in light
188 gray (N=21) vs. those who deferred ART initiation for 24 weeks in dark gray (N=26), with mean
189 differences (dots) and 95% confidence intervals (lines) shown. The 95% confidence intervals were
190 calculated based on a regression analysis with values log transformed prior to analysis and differences
191 divided by pre-infection standard deviation for each analyte. The vertical dotted line reflects no difference
192 between post- and pre-infection values.

193 Abbreviations: suPAR, soluble urokinase-type plasminogen activator receptor; sCD14 and sCD163,
194 soluble cluster of differentiation 14 and 163; LBP, lipopolysaccharide binding protein; IL-1 β , IL-6, IL-8
195 and IL-10, interleukin 1b, 6, 8 and 10; IFN- γ and IFN- α 2a, interferon-gamma and -alpha 2a; IP-10,
196 interferon gamma-induced protein 10; MCP-1/CCL2, monocyte chemoattractant protein-1; TNF- α , tumor
197 necrosis factor-alpha; CRP, C-reactive protein

198
199

200 A comparison of sCD14 values between Visit-3 and -4 in participants (N=43) who switched from
201 efavirenz- to non-efavirenz-based regimens found no significant changes between these intervals.

202

203 **DISCUSSION**

204 This study is unique in documenting changes in biomarkers of immune activation in individuals with
205 prospectively documented incident HIV infection, and in examining differences in biomarkers between
206 participants randomized to initiate ART immediately in early infection or to defer ART for 24 weeks.

207 Comparison of biomarkers from pre-infection to post ART-suppression, including correction for multiple
208 comparisons, showed increased plasma levels of proinflammatory chemokines/cytokines MCP-1/CCL2
209 and IP-10 secreted by monocyte/macrophages and other cell types in response to HIV infection (27, 28)
210 or stimulation by cytokines (29), and CRP, a marker of inflammation associated with infections, cancers,
211 auto-immunity or tissue damage. These findings of elevated inflammatory cytokines/chemokines are
212 consistent with those reported by previous studies (4, 6, 7, 30). In addition, the levels of one biomarker,
213 leptin, were lower in the post-infection compared to pre-infection specimens. The decrease in leptin, a
214 marker of energy expenditure (31), is consistent with previous studies finding lower leptin in ART-treated
215 PWH (32), likely due to HIV-infection-induced catabolism.

216

217 Multiple biomarkers, including IP-10, IL-6, sCD163, leptin, IL-8, and LBP were variable either within
218 each participant's two pre-infection or two post-ART-suppression specimens. Temporal perturbations in
219 these analytes may have occurred due to intercurrent illnesses, alcohol consumption (33, 34), or other
220 unknown reasons. The observed intraparticipant variation suggests that a determination of these analytes
221 at a single point in time may be unreliable in assessing an individual's biomarker levels and supports the
222 use of large datasets to explore relationships between HIV infection and markers of immune activation.

223

224 Our comparison of biomarker levels between those who initiated immediate- versus deferred-ART
225 initiation found that those treated immediately had significantly less elevation of their CRP and LBP

226 values. Earlier initiation of ART limits the size of the persistent viral reservoir (35), which should limit
227 production of viral nucleic acids and proteins that others have found associated with progression of
228 carotid artery intima thickness (13) or atherosclerotic plaque (14). The greater decrease in plasma IFN-
229 α 2a observed among those deferring ART (**Figure 2**) may be attributable to consistently high pre-
230 infection values in this group. Notably, during ART all participants had IFN- α 2a values in the normal
231 range of the assay (**Figure 1**).

232
233 While efavirenz in prior studies was associated with elevated sCD14 and kynurenine-tryptophan ratio (8,
234 36), we did not observe a significant change in sCD14 in participants who switched from efavirenz-based
235 ART to a “non-efavirenz” elvitegravir-based regimen. It is not known whether elvitegravir (or cobicistat,
236 contained in the co-formulated product to reduce hepatic clearance of elvitegravir) is associated with
237 inflammation, but it is notable that sCD14 levels were in the normal range for all specimens tested in the
238 study.

239
240 The primary limitations of this study are the relatively small size of the cohort examined, a relatively
241 short follow-up of the ART-suppressed participants for this life-long infection and the assessment of
242 biomarkers from relatively few timepoints. In addition, the relative youth of our study participants and the
243 short duration of their HIV infections limited our ability to observe non-AIDS adverse events, and we
244 were unable to conduct long term follow-up to observe and correlate our findings with clinical events.
245 Additionally, when evaluating the potential impact of efavirenz, we did not test some biomarkers found to
246 be abnormal in other studies, e.g., kynurenine/tryptophan ratio (8, 36). The primary strength of this study
247 comes from the comparison of two samples from before and two after documented incident HIV
248 infection. The two specimens prior and two after infection reduces variability due to extraneous events.
249 The study of individuals with incident infection diminishes the biases due to pre-existing conditions and
250 confounding behavioral practices, although, we acknowledge that behaviors may change following HIV
251 diagnosis (37).

252

253 **CONCLUSIONS**

254 In conclusion, multiple pro-inflammatory biomarkers appear to have been induced by HIV and/or ART,
255 despite virologic suppression. Importantly, ART initiation during acute/early HIV infection appeared to
256 limit CRP levels. Given the strong association of CRP with cardiovascular disease (38, 39), these findings
257 emphasize that HIV prevention and ART initiation during primary infection could diminish non-AIDS
258 events.

259

260 **ACKNOWLEDGEMENTS and FUNDING**

261 The authors acknowledge the contributions of the study participants, site investigators and staff. The
262 study drug was provided at no cost to the Institution by Merck Sharp & Dohme Corp. The opinions
263 expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp &
264 Dohme Corp.

265 The project was funded by NIH R01 DA040532 (ACD). Additional support came from the Molecular
266 Profiling and Computational Biology Core of the University of Washington and Fred Hutch Center for
267 AIDS Research (award number P30 AI027757), from the Laboratory Core of International Maternal
268 Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) UM1 AI106716 (Subaward: LMF). This
269 work was also supported by the National Center For Advancing Translational Sciences of the National
270 Institutes of Health under Award Number KL2 TR002317 (GG). The content is solely the responsibility
271 of the authors and does not necessarily represent the official views of the National Institutes of Health.

272

273 **SEQUENCE DATA**

274

275

276 Nucleotide consensus sequences are available in the NCBI Genbank under accession numbers (pending
277 manuscript acceptance). Illumina data are available in the NCBI Sequence Read Archive under
278 BioProject number (pending manuscript acceptance).

279

280 REFERENCES

- 281 1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The
282 efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex.
283 *New England Journal of Medicine*. 1987;317(4):185-91.
- 284 2. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease
285 inhibitor therapy and outcomes in patients with HIV infection. *Annals of internal medicine*.
286 2000;133(1):21-30.
- 287 3. Zolopa AR, Andersen J, Komarow L, Sanne I, Sanchez A, Hogg E, et al. Early antiretroviral
288 therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter
289 randomized strategy trial. *PloS one*. 2009;4(5):e5575.
- 290 4. Hellmuth J, Slike BM, Sacdalan C, Best J, Kroon E, Phanuphak N, et al. Very early initiation of
291 antiretroviral therapy during acute HIV infection is associated with normalized levels of immune
292 activation markers in cerebrospinal fluid but not in plasma. *The Journal of infectious diseases*.
293 2019;220(12):1885-91.
- 294 5. Sunil M, Nigalye M, Somasunderam A, Martinez ML, Yu X, Arduino RC, et al. Unchanged
295 levels of soluble CD14 and IL-6 over time predict serious non-AIDS events in HIV-1-infected people.
296 *AIDS research and human retroviruses*. 2016;32(12):1205-9.
- 297 6. Sereti I, Krebs SJ, Phanuphak N, Fletcher JL, Slike B, Pinyakorn S, et al. Editor's choice:
298 Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute
299 HIV Infection. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of
300 America*. 2017;64(2):124.
- 301 7. Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect
302 of HAART-induced HIV suppression on circulating markers of inflammation and immune activation.
303 *AIDS (London, England)*. 2015;29(4):463.
- 304 8. Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, York VA, Hartig H, et al. Abnormal
305 Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human
306 Immunodeficiency Virus. *The Journal of Infectious Diseases*. 2021;223(9):1621-30.
- 307 9. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of
308 antiretroviral therapy in early asymptomatic HIV infection. *The New England journal of medicine*.
309 2015;373(9):795-807.
- 310 10. Temprano ANS 12136 Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and
311 isoniazid preventive therapy in Africa. *New England Journal of Medicine*. 2015;373(9):808-22.
- 312 11. Rasmussen LD, May MT, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, et al. Time trends for
313 risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a
314 nationwide population-based cohort study. *The lancet HIV*. 2015;2(7):e288-e98.
- 315 12. de Paula HHS, Ferreira ACG, Caetano DG, Delatorre E, Teixeira SLM, Coelho LE, et al.
316 Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not in
317 early chronic HIV-1 infection. *Retrovirology*. 2018;15(1):1-11.

- 318 13. McLaughlin MM, Ma Y, Scherzer R, Rahalkar S, Martin JN, Mills C, et al. Association of Viral
319 Persistence and Atherosclerosis in Adults With Treated HIV Infection. *JAMA Netw Open*.
320 2020;3(10):e2018099.
- 321 14. Turcotte I, El-Far M, Sadouni M, Chartrand-Lefebvre C, Filali-Mouhim A, Fromentin R, et al.
322 Association Between the Development of Subclinical Cardiovascular Disease and Human
323 Immunodeficiency Virus (HIV) Reservoir Markers in People With HIV on Suppressive Antiretroviral
324 Therapy. *Clin Infect Dis*. 2023;76(7):1318-21.
- 325 15. Morgan E, Taylor HE, Ryan DT, D'Aquila R, Mustanski B. Systemic inflammation is elevated
326 among both HIV-uninfected and-infected young men who have sex with men. *AIDS (London, England)*.
327 2019;33(4):757.
- 328 16. Lama JR, Brezak A, Dobbins JG, Sanchez H, Cabello R, Rios J, et al. Design strategy of the
329 Sabes Study: diagnosis and treatment of early HIV infection among men who have sex with men and
330 transgender women in Lima, Peru, 2013–2017. *American journal of epidemiology*. 2018;187(8):1577-85.
- 331 17. Lama JR, Ignacio RAB, Alfaro R, Rios J, Cartagena JG, Valdez R, et al. Clinical and
332 immunologic outcomes after immediate or deferred antiretroviral therapy initiation during primary human
333 immunodeficiency virus infection: the Sabes randomized clinical study. *Clinical Infectious Diseases*.
334 2021;72(6):1042-50.
- 335 18. Grebe E, Facente SN, Bingham J, Pilcher CD, Powrie A, Gerber J, et al. Interpreting HIV
336 diagnostic histories into infection time estimates: analytical framework and online tool. *BMC infectious*
337 *diseases*. 2019;19(1):1-10.
- 338 19. Nabatanzi R, Bayigga L, Cose S, Rowland Jones S, Joloba M, Canderan G, et al. Monocyte
339 dysfunction, activation, and inflammation after long-term antiretroviral therapy in an African Cohort. *The*
340 *Journal of infectious diseases*. 2019;220(9):1414-9.
- 341 20. Brites-Alves C, Luz E, Netto EM, Ferreira T, Diaz RS, Pedroso C, et al. Immune activation,
342 proinflammatory cytokines, and conventional risks for cardiovascular disease in HIV patients: a case-
343 control study in Bahia, Brazil. *Frontiers in immunology*. 2018;9:1469.
- 344 21. Hoenigl M, Moser CB, Funderburg N, Bosch R, Kantor A, Zhang Y, et al. Soluble urokinase
345 plasminogen activator receptor is predictive of non-aids events during antiretroviral therapy-mediated
346 viral suppression. *Clinical Infectious Diseases*. 2019;69(4):676-86.
- 347 22. Siedner MJ, Bwana MB, Asimwe S, Amanyire G, Musinguzi N, Castillo-Mancilla J, et al.
348 Timing of antiretroviral therapy and systemic inflammation in sub-Saharan Africa: results from the
349 META longitudinal cohort study. *The Journal of infectious diseases*. 2019;220(7):1172-7.
- 350 23. Babu H, Ambikan AT, Gabriel EE, Svensson Akusjärvi S, Palaniappan AN, Sundaraj V, et al.
351 Systemic inflammation and the increased risk of inflamm-aging and age-associated diseases in people
352 living with HIV on long term suppressive antiretroviral therapy. *Frontiers in immunology*. 2019;10:1965.
- 353 24. Subramanya V, McKay HS, Brusca RM, Palella FJ, Kingsley LA, Witt MD, et al. Inflammatory
354 biomarkers and subclinical carotid atherosclerosis in HIV-infected and HIV-uninfected men in the
355 Multicenter AIDS Cohort Study. *PloS one*. 2019;14(4):e0214735.

- 356 25. Tarantino G, Costantini S, Citro V, Conforti P, Capone F, Sorice A, et al. Interferon-alpha 2 but
357 not Interferon-gamma serum levels are associated with intramuscular fat in obese patients with
358 nonalcoholic fatty liver disease. *Journal of translational medicine*. 2019;17(1):1-14.
- 359 26. Paul RF, Hassan M, Nazar HS, Gillani S, Afzal N, Qayyum I. Effect of body mass index on
360 serum leptin levels. *J Ayub Med Coll Abbottabad*. 2011;23(3):40-3.
- 361 27. Deshmane SL KS, Amini S, Sawaya BE. Monocyte Chemoattractant Protein-1 (MCP-1): An
362 Overview. *J Interferon Cytokine Res*. 2009;29(6):313-26.
- 363 28. Luster AD RJ. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). *J*
364 *Exp Med*. 1987;166(4):1084-7.
- 365 29. Shi C, Pamer, E. Monocyte recruitment during infection and inflammation. *Nat Rev Immunol*.
366 2011;11:762-74.
- 367 30. Bordoni V, Sacchi A, Casetti R, Cimini E, Tartaglia E, Pinnetti C, et al. Impact of ART on
368 dynamics of growth factors and cytokines in primary HIV infection. *Cytokine*. 2020;125:154839.
- 369 31. Pérez-Pérez A S-JF, Vilariño-García T, Sánchez-Margalet V. Role of Leptin in Inflammation and
370 Vice Versa. *Int J Mol Sci*. 2020;21(16):5887. Published 2020 Aug 16. doi:10.3390/ijms21165887. Role
371 of Leptin in Inflammation and Vice Versa. *Int J Mol Sci*. 2020;21(16).
- 372 32. Tiliscan C, Aramă V, Mihăilescu R, Munteanu DI, Streinu-Cercel A, Ion DA, et al. Leptin
373 expression in HIV-infected patients during antiretroviral therapy. *Germs*. 2015;5(3):92.
- 374 33. Achur RN, Freeman WM, Vrana KE. Circulating cytokines as biomarkers of alcohol abuse and
375 alcoholism. *Journal of Neuroimmune Pharmacology*. 2010;5(1):83-91.
- 376 34. Leclercq S, Cani PD, Neyrinck AM, Stärkel P, Jamar F, Mikolajczak M, et al. Role of intestinal
377 permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects.
378 *Brain, behavior, and immunity*. 2012;26(6):911-8.
- 379 35. Tagarro A, Chan M, Zangari P, Ferns B, Foster C, De Rossi A, et al. Early and highly suppressive
380 ART are main factors associated with low viral reservoir in european perinatally HIV infected children.
381 *Journal of acquired immune deficiency syndromes (1999)*. 2018;79(2):269.
- 382 36. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, et al. Inflammation
383 markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or
384 atazanavir/ritonavir: ACTG A5224 s, A5202 substudy. *AIDS (London, England)*. 2012;26(11):1371.
- 385 37. Cleary PD, Van Devanter N, Rogers TF, Singer E, Shipton-Levy R, Steilen M, et al. Behavior
386 changes after notification of HIV infection. *American journal of public health*. 1991;81(12):1586-90.
- 387 38. Elias-Smale SE, Kardys I, Oudkerk M, Hofman A, Witteman JC. C-reactive protein is related to
388 extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study.
389 *Atherosclerosis*. 2007;195(2):e195-e202.
- 390 39. Laaksonen DE, Niskanen L, Nyssönen K, Punnonen K, Tuomainen T-P, Salonen JT. C-reactive
391 protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based
392 cohort study. *European heart journal*. 2005;26(17):1783-9.




Figure 1




Figure 2